DNTH — Dianthus Therapeutics, Inc. /DE/

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1690585 ·
Last close
$86.98
Market Cap
$4.90B
52W High
$117.88
52W Low
$35.84
ADV30
901,788
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,210,000 — -58,472,000 -46,643,000 1,276,252,000 55,686,000 34,823,000
Jun 2026 761,000 — -61,482,000 -50,215,000 1,213,271,000 110,549,000 41,246,000
Mar 2026 463,000 — -46,533,000 -40,834,000 1,246,884,000 627,667,000 45,570,000
Dec 2025 284,000 — -69,541,000 -64,432,000 530,922,000 51,087,000 37,521,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-175,154,000
Investing CF
$-687,161,000
Financing CF
$862,146,000
CapEx
$-697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.99
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-474,421,000
Inventory
—
Receivables
$582,000
ST Investments
$782,097,000
EBIT TTM
$-236,028,000
Pretax Income TTM
$-202,124,000
Interest Exp TTM
—
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,718,000
EBITDA
$-235,895,008
Free Cash Flow
$-109,141,504
Enterprise Value
$4,008,007,680
Total Cash
$837,782,976
Total Debt
$1,208,000
Shares Out
56,312,712
Trailing EPS
$-4.08
Book Value
$22.05
ROE
-22.6%
ROA
-15.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,036,000 -177,933,000 -162,337,000 530,922,000 37,521,000 493,401,000 -129,060,000
Dec 2024 6,235,000 -101,864,000 -84,969,000 374,008,000 21,531,000 352,477,000 -78,180,000
Dec 2023 2,826,000 -48,174,000 -43,555,000 179,405,000 10,535,000 168,870,000 -36,861,000
Dec 2022 6,417,000 -29,705,000 -28,476,000 83,110,000 9,454,000 73,656,000 -29,070,000

TTM Snapshot

Revenues TTM
$1,904,000
NetIncome TTM
$-192,246,000
OpCashFlow TTM
—
Assets (Latest)
$1,213,271,000
Forward EPS
$-4.61

Max Pain — expiry 2026-12-18

max pain strike: $75.00 · spot: $83.98 · call oi: 1,063 · put oi: 1,501

Peers — same industry

TickerNameMarket CapLastDaily %
TVTX Travere Therapeutics, Inc. $4.91B $51.10 —
ERAS Erasca, Inc. $4.87B $13.89 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —
PTCT PTC THERAPEUTICS, INC. $5.04B $60.36 —
LQDA Liquidia Corp $5.11B $56.73 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
2026-11-09 13:55 · Yahoo
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 21:15 · Yahoo
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
2026-11-04 21:01 · Yahoo
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 22:00 · Yahoo
Dianthus Therapeutics to Participate in Five Investor Conferences During November
2026-11-02 21:01 · Yahoo
Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
2026-10-20 09:15 · Yahoo
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
2026-10-13 13:52 · Yahoo
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
2026-10-13 12:45 · Yahoo
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
2026-09-29 12:00 · Yahoo
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
2026-09-24 08:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.